Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered to discuss cutting-edge developments, and the Image of the Year was a novel peptide-based PET tracer targeting PD-L1 in head and neck cancers.
Sessions covered the latest in tracer development, theranostics, total-body PET, and AI-powered imaging strategies. The apparent excitement and rapid learning between established researchers and rising talent underscore how quickly the field is evolving.
These innovations are more than academic—they inform the development of better diagnostic tools and smarter clinical trial designs. Axcellant is excited to apply insights from SNMMI 2025 to strengthen our imaging‑focused clinical research services, helping advance patient care through precision and innovation.
Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…
How Axcellant stabilized isotope supply, synchronized global imaging operations, and prevented a multi-month program delay. At a Glance Study type:…
At Axcellant, we work where medtech becomes real, not in headlines but in clinics, documentation, and decisions that must stand…
Copyright @ 2026 Axcellant